Rationale

RationAle Brewing™ 'Rips into Right Now' Fueled by a Bold Brand Identity & Packaging, Refined Formulations and Expanded Capacity to 70K Barrels

Retrieved on: 
Wednesday, October 4, 2023

SAN DIEGO, Oct. 4, 2023 /PRNewswire-PRWeb/ -- Trailblazing a revolution in the dynamic non-alcoholic (NA) craft beer category, RationAle Brewing™ today unveiled the rollout of its unapologetic Maverick identity, bold new carton packaging, and reformulated brews, as it continues its rapidly expanding distribution and widespread consumer adoption.

Key Points: 
  • With relentless ambition and enthusiasm, RationAle has staked its claim as the 5th largest NA Craft Beer, according to SPINS August reporting.
  • Eyes firmly on the prize, the team is revved up and ready to secure the #2 spot in the rapidly growing craft non-alcoholic market.
  • "We are not just reinforcing our brand positioning; we are redefining the non-alcoholic beer landscape and what the consumer expects of it.
  • For those intrigued by the Maverick way of life and keen to learn more about RationAle Brewing, visit www.rationalebrewing.com and follow @RationAleBrewing on Instagram.

Olatec Therapeutics Announces the Completion of First Dose Cohort in an Innovative Trial Investigating Olatec’s NLRP3 Inhibitor Dapansutrile and Merck’s Keytruda® in Patients with Advanced Refractory Melanoma at Duke Cancer Institute

Retrieved on: 
Tuesday, May 16, 2023

This trial is evaluating the combination treatment of Olatec’s dapansutrile, an NLRP3 inhibitor, and pembrolizumab (Keytruda®) in patients with PD-1 refractory advanced melanoma.

Key Points: 
  • This trial is evaluating the combination treatment of Olatec’s dapansutrile, an NLRP3 inhibitor, and pembrolizumab (Keytruda®) in patients with PD-1 refractory advanced melanoma.
  • The study is being led by Principal Investigator (PI), April Salama MD, Head of the Melanoma Program at The Duke Cancer Research Institute and supported by Olatec and Merck & Co., Inc. (Merck).
  • The aim of the DREAM Trial is to address the unmet need in patients with PD-1 refractory advanced melanoma.
  • Immunotherapy with immune checkpoint inhibitors (e.g., anti-PD-1 therapies) has transformed the treatment of melanoma, significantly improving the outcome of patients with this disease.

RationAle Brewing™ Announces Appointment of Co-Founder Wendy Pickett as Executive Vice President of Sales, Alongside Securing New Distributor Partnerships in California

Retrieved on: 
Tuesday, January 31, 2023

SAN DIEGO, Jan. 31, 2023 /PRNewswire-PRWeb/ -- RationAle Brewing™, the San Diego-born, Sonoma-brewed non-alcoholic craft beer brand, has solidified its presence and furthered its sales-support strategy on the West Coast, with the announcement of its new distributor partnerships across California and the appointment of Co-Founder Wendy Pickett as Executive Vice President of Sales.

Key Points: 
  • As part of her new EVP Sales role, Pickett will be focusing on retail chain accounts, in-store execution and building best-in-class distributor partnerships for the brand across all existing markets as well as nationwide.
  • "I could not be more energized to be working with our incredible team of founding friends, brewery partners, brand ambassadors and avid RationAle Brewing consumers, across the country" shares Pickett.
  • In addition to brand growth news, RationAle Brewing also launched a 'Wet January' campaign to encourage moderation and mindful drinking habits, this past month.
  • All of RationAle Brewing's completely-crushable, non-alcoholic craft brews are made in small batches with high-quality ingredients, maintaining the bold, refreshing taste of traditional craft beer.

Baxter Highlights New Home Dialysis and HDx Therapy Data in 14 Clinical Presentations at Kidney Week 2022

Retrieved on: 
Monday, November 7, 2022

Baxter International Inc. (NYSE:BAX), a global innovator in kidney care, advanced scientific exchange with 14 new data presentations about the role innovation plays in increasing access to and quality of home dialysis and expanded hemodialysis (HDx) care at Kidney Week 2022, Nov. 3-6, Orlando, Florida.

Key Points: 
  • Baxter International Inc. (NYSE:BAX), a global innovator in kidney care, advanced scientific exchange with 14 new data presentations about the role innovation plays in increasing access to and quality of home dialysis and expanded hemodialysis (HDx) care at Kidney Week 2022, Nov. 3-6, Orlando, Florida.
  • Scientific exchange is an important part of the collaboration and education initiatives, which we are very pleased to support at this years Kidney Week.
  • Baxter, Sharesource and Theranova are registered trademarks of Baxter International Inc.
    1 Hutchison CA, Wolley M. The Rationale for Expanded Hemodialysis Therapy.
  • Long Term Effects of Expanded Hemodialysis (HDx) on Clinical and Laboratory Parameters in a Large Cohort of Dialysis Patients.

Longeveron Announces Abstract Accepted for Presentation at the Alzheimer’s Association International Conference (AAIC)

Retrieved on: 
Thursday, July 7, 2022

We are pleased that the AAICthe premier organization in ADhas accepted our poster describing the design of Longeverons second study in Alzheimers Disease.

Key Points: 
  • We are pleased that the AAICthe premier organization in ADhas accepted our poster describing the design of Longeverons second study in Alzheimers Disease.
  • Earlier this year, Longeveron published a peer-reviewed study of its Phase 1b Alzheimer's Disease trial in Alzheimers & Dementia showing that the trial met its primary endpoint, demonstrating that Lomecel-B was well tolerated in this patient population.
  • Longeveron is a clinical stage biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions.
  • Longeveron is currently sponsoring Phase 1 and 2 clinical trials in the following indications: Alzheimers Disease, hypoplastic left heart syndrome (HLHS), Aging Frailty, and Acute Respiratory Distress Syndrome (ARDS).

RationAle Brewing Appoints CPG Sales, Commercial and Operational Leader, Bryan Carlin, as Chief Growth Officer to Scale U.S. Distribution

Retrieved on: 
Friday, June 3, 2022

SAN DIEGO, Calif., June 3, 2022  /PRNewswire-PRWeb/ --

Key Points: 
  • As Chief Growth Officer, Carlin will lead the company's growth efforts, including the buildout of its team and strategic partnerships with distributors and retailers, fueling the expansion of RationAle Brewing into new markets and beer fridges, across the West Coast and beyond.
  • "Bryan is a CPG street warrior who has been alongside me in the trenches many times over, throughout our careers together," shares Jamie Fay, Founder and CEO of RationAle Brewing.
  • All of RationAle's flavor-forward brews are made with high-quality ingredients and in small batches, mimicking the bold, refreshing taste of traditional craft beer.
  • RationAle Brewing offers an innovative variety of small-batch, non-alcoholic craft beers for those seeking to embrace moderation while drinking consciously and living boldly.

Affimed Presents Data on Innate Cell Engagers AFM24 and AFM28 at 19th Meeting of the Society for Natural Immunity

Retrieved on: 
Monday, May 16, 2022

Preclinical data have shown that AFM24 can induce NK cell-mediated killing of EGFR-positive solid tumor cell lines, independent of EGFR mutational status.

Key Points: 
  • Preclinical data have shown that AFM24 can induce NK cell-mediated killing of EGFR-positive solid tumor cell lines, independent of EGFR mutational status.
  • The AFM28 poster featured preclinical data on the anti-leukemic activity of the compound when pre-complexed and co-administered with allogeneic NK cells.
  • AFM28 is a tetravalent, bispecific innate cell engager (ICE) that activates the innate immune system by binding to CD16A on innate immune cells and CD123-positive cells on myeloid malignancies.
  • The ROCK platform predictably generates customized innate cell engager (ICE) molecules, which use patients immune cells to destroy tumor cells.

Cytokinetics Reports First Quarter 2022 Financial Results

Retrieved on: 
Wednesday, May 4, 2022

SOUTH SAN FRANCISCO, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) reported financial results for the first quarter of 2022. Net loss for the first quarter was $89.4 million, or $1.05 per share, compared to net loss for the first quarter of 2021 of $47.1 million, or $0.66 per share. Cash, cash equivalents and investments totaled $686.1 million at March 31, 2022.

Key Points: 
  • Initial Data from REDWOOD-HCM OLE, the Open Label Extension Study of Aficamten, to be Presented at Heart Failure 2022 on May 23, 2022
    Continued Launch Readiness Activities and Buildout of Commercial Infrastructure in Advance of PDUFA Date of November 30, 2022 for Omecamtiv Mecarbil
    SOUTH SAN FRANCISCO, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) reported financial results for the first quarter of 2022.
  • Revenues for the first quarter 2022 were $1.1 million compared to $6.5 million for the corresponding period in 2021.
  • Members of Cytokinetics senior management team will review the companys first quarter results on a conference call today at 4:30 PM Eastern Time.
  • CYTOKINETICS and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.

Longeveron Announces Fourth Quarter and Full Year 2021 Financial Results and Operational Progress

Retrieved on: 
Friday, March 11, 2022

For Longeveron, 2021 was a year defined by effective execution, successful financings, and significant progress across our robust Lomecel-B pipeline of clinical trials, said Geoff Green, Chief Executive Officer at Longeveron.

Key Points: 
  • For Longeveron, 2021 was a year defined by effective execution, successful financings, and significant progress across our robust Lomecel-B pipeline of clinical trials, said Geoff Green, Chief Executive Officer at Longeveron.
  • In fourth quarter 2021, the U.S. FDA granted Rare Pediatric Disease Designation and Orphan Drug Designation to Lomecel-B for the treatment of infants with HLHS.
  • Net Loss: Net loss was $4.1 million in the fourth quarter of 2021 compared to $1.4 million for the same period in 2020.
  • Management will host a conference call today at 8:30 a.m. Eastern Time to discuss the Companys fourth quarter and year end 2021 financial results and provide a business update.

Longeveron Announces Publication of Lomecel-B Phase 2b Trial Design in Journal of Frailty and Aging

Retrieved on: 
Wednesday, January 12, 2022

MIAMI, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or the "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and certain life-threatening conditions, announced today publication of the design and rationale from its recently completed Phase 2b aging frailty clinical trial with Lomecel-B in the Journal of Frailty and Aging .

Key Points: 
  • MIAMI, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or the "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and certain life-threatening conditions, announced today publication of the design and rationale from its recently completed Phase 2b aging frailty clinical trial with Lomecel-B in the Journal of Frailty and Aging .
  • This peer-reviewed article describes the design of the trial which investigated Lomecel-B, a living cell therapy product, as a regenerative medicine strategy for the treatment of frailty in older adults.
  • Aging Frailty is a life-threatening geriatric condition, which studies have estimated affect approximately 15% of Americans over the age of 65, or 8.1 million individuals.
  • Despite the pressing need for interventions, there are no FDA-approved therapies that can slow down, reverse, or prevent Aging Frailty.